Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2016 (the third quarter of fiscal 2016), not 2015 Q3 as indicated in the request metadata. Financial statements are unaudited.
Business context
Palatin is a development-stage biopharmaceutical company with no product sales. Its lead program is bremelanotide for female sexual dysfunction (FSD); other programs include PL-3994 and MC1r and MC4r candidates. The company relies on financing and collaborations to fund research and development.
Key financial results
| Metric | Three months ended March 31, 2016 | Three months ended March 31, 2015 | Nine months ended March 31, 2016 | Nine months ended March 31, 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $12.95 million |
| Research and development | $10.68 million | $7.59 million | $32.55 million | $14.79 million |
| General and administrative | $1.41 million | $1.13 million | $3.97 million | $3.67 million |
| Net loss | $12.70 million | $9.15 million | $38.36 million | $5.58 million |
| Basic and diluted loss per share | $0.08 | $0.07 | $0.25 | $0.05 |
- Quarterly R&D expense increased about 41%, primarily due to continued Phase 3 bremelanotide trials. Nine-month R&D more than doubled year over year. Quarterly G&A also rose, mainly due to stock-based compensation.
- The prior-year nine-month period included $12.95 million of Gedeon Richter license and milestone revenue; the current period had none. The company terminated that agreement in September 2015, and the rights reverted to Palatin.
- For the nine months ended March 31, 2016, operating cash use was $33.66 million, versus $3.89 million a year earlier. Investing cash use was $1.40 million. Financing provided $29.54 million, principally from a warrant private placement and venture debt.
- At March 31, 2016, cash and cash equivalents were $21.77 million and available-for-sale investments were $1.38 million, totaling $23.15 million. Current assets were $24.64 million and current liabilities were $13.09 million.
- Notes payable had a net carrying value of $19.63 million, including $3.48 million current and $16.15 million long term. The two venture loans have $20 million aggregate principal, floating interest at one-month LIBOR (minimum 0.50%) plus 8.50%, and are secured by substantially all assets other than intellectual property. Palatin reported covenant compliance.
- Stockholders’ equity moved from $12.20 million at June 30, 2015 to a deficit of $4.70 million at March 31, 2016. No gross margin is reported because the company recorded no current-period revenue.
Outlook, risks and unusual items
- Patient enrollment in the Phase 3 bremelanotide trials was complete; last-patient-out and topline results were projected for the third quarter of calendar 2016. The filing cautions that trial success and FDA approval are uncertain.
- Management estimated the bremelanotide Phase 3 program, including regulatory filings, would cost at least $80 million, with approximately $48 million expensed to date. Management said existing capital resources were expected to fund planned operations through the quarter ending September 30, 2016; additional financing will be needed for further development and regulatory work. The company expected significant losses to continue.
- Key risks include clinical or regulatory failure or delay, limited access to additional capital, reliance on third-party trial and manufacturing contractors, competition, uncertain reimbursement and market acceptance, and potential dilution. The company also disclosed substantial outstanding warrants and financing participation rights granted to certain investors.
- The filing reports no current legal proceedings. Management concluded disclosure controls were effective as of March 31, 2016, with no material quarterly change in internal control over financial reporting.
- Reported weighted-average shares for EPS substantially exceed period-end common shares because certain nominal-exercise-price warrants are included in the EPS calculation. The filing reports 68.04 million common shares outstanding at March 31, 2016, and 68,040,008 shares as of May 11, 2016.
Most important facts to verify
- Confirm the actual bremelanotide Phase 3 topline results, FDA path and remaining program costs against the filing’s projections.
- Assess the financing runway: management’s stated September 30, 2016 funding horizon, current cash and investments, and anticipated capital needs.
- Review debt terms, amortization schedule, prepayment penalties, collateral and any later covenant or financing developments.
- Reconcile the disclosed $48 million of bremelanotide spending to date with the separate cumulative program-spending disclosure of approximately $224.5 million.
- Evaluate potential dilution and share-count presentation, including warrants, options, restricted stock units and preferred stock.